Chemical structure of Thapsigargin.
Western blot analysis of extracts from HeLa cells, untreated (-) or treated with Thapsigargin (2 nM, 16 hr; +), using OS-9 (D8P4G) Rabbit mAb #12497 (upper) and GAPDH (D16H11) XP® Rabbit mAb #5174 (lower).
Western blot analysis of extracts from C2C12 cells, untreated (-) or treated with Thapsigargin (300 nM, 30 min; +), using Phospho-eIF2α (Ser51) (D9G8) XP® Rabbit mAb #3398 (upper) and eIF2α Antibody #9722 (lower).
Thapsigargin is supplied as a lyophilized powder. For a 1.25 mM stock, reconstitute the 1 mg in 1.23 ml DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 2-2000 nM for 0.5-24 hours.
Solubility: Soluble in DMSO or ethanol.
Store lyophilized or in solution at -20ºC, dessicated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once reconstituted, chemical is stable for 1 week when stored at -20C. Aliquot to avoid multiple freeze/thaw cycles.
Thapsigargin is a cell-permeable sesquiterpene lactone derived from the plant Thapsia garganica that acts as a tumor promoter in mammalian cells (1,2). Studies show that thapsagargin causes a rapid increase in cytosolic Ca2+ concentrations via discharge of intracellular Ca2+ stores. Research indicates that this increase in cytosolic calcium results from the specific inhibition of endoplasmic reticulum Ca2+-ATPases (IC50 = ~30 nM), and does not involve the hydrolysis of inositol phospholipids or protein kinase C (1,2). This disruption of calcium homeostasis is widely used in research studies to induce ER stress. Conflicting information regarding the role of thapsigargin in autophagy has been reported, but recent evidence points to thapsigargin inhibiting autophagy by blocking autophagosome fusion with lysosomes (3-5).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.